inquest

Candidate drug-failure mechanisms from the public record: claim-anchored, with confidence and provenance.

precomputed

Trial

Verified terminated-trial assets, precomputed for instant lookup. Run live regenerates the selected memo from the public record (about 5 to 10 min).

Mechanism

Off target receptor binding

Cardiotoxicity hemodynamic

Torcetrapib's excess mortality in ILLUMINATE is best explained by an off-target pharmacological effect rather than by its on-target CETP inhibition. The molecule stimulated adrenal aldosterone and cortisol synthesis through an intracellular calcium-mediated pathway independent of CETP, producing dose-related increases in blood pressure, serum sodium and bicarbonate, and a fall in potassium. These haemodynamic and electrolyte changes - not the large HDL-cholesterol rise the drug achieved - track with the increased rate of cardiovascular death and morbidity that prompted the Data Safety Monitoring Board to halt the trial. The off-target reading is reinforced by the absence of comparable mortality signals in later, structurally distinct CETP inhibitors.

Molecular lever: Off-target induction of adrenal aldosterone and cortisol synthesis (calcium-mediated), raising blood pressure and shifting electrolytes

84%

confidence

clamped 5–95% · never certain5–30% low: sparse or conflicting public evidence30–60% moderate: consistent but partial evidence60–95% high: convergent peer-reviewed and regulatory evidence

Claim-anchored verification

Anchored on

Citations (3)

Alternative hypotheses (2)▸

On target class toxicityscore 0.41
CETP inhibition yields large but dysfunctional HDL, conferring no benefit and possible harm as a class effect shared across CETP inhibitors.
Ion channel blockscore 0.22
A speculative off-target electrophysiological effect prolonging QT; little direct public evidence supports it for torcetrapib.

Verification scorecard (5 sub-claims)▸

3 supported1 contradicted1 unsupported

supported
Torcetrapib raised blood pressure in a dose-dependent manner.
ILLUMINATE reported a mean systolic blood-pressure increase of roughly 5 mmHg versus placebo.
supported
The drug stimulated aldosterone synthesis independent of CETP inhibition.
Adrenal-cell studies show calcium-mediated aldosterone and cortisol induction with no CETP involvement.
supported
Excess deaths were cardiovascular and consistent with a pressor/electrolyte effect.
Mortality and cardiovascular events rose despite a substantial HDL-cholesterol increase.
contradicted
The harm is an on-target CETP-class toxicity.
Structurally distinct CETP inhibitors did not reproduce the mortality signal, arguing against a class effect.
unsupported
A reactive-metabolite mechanism accounts for the deaths.
No reactive-metabolite or hepatotoxicity signal is documented in the public record for torcetrapib.

Provenance trail▸

Model versions: node_1_retrievalanthropic/claude-haiku-4.5
node_2_generatorgoogle/gemini-2.5-pro
node_3_criticopenai/gpt-5
node_4_synthesisanthropic/claude-sonnet-4.6
Aggregation weights (deterministic, no model call): w_s=1 w_c=1 w_u=0.3 w_specificity=0.5 w_p=0.3

claude-haiku-4.5 / gemini-2.5-pro / gpt-5 / claude-sonnet-4.6 · run 2026-05-25 18:42 · $1.64 · temp=0